Faced With Paying For Pricey GeneTherapy Treatments Insurers Start Thinking Outside The Box

Faced With Paying For Pricey Gene-Therapy Treatments, Insurers Start Thinking Outside The Box

08:34 EDT 6 Sep 2019 | Kaiser Health News

The expensive new therapies can be life-changing, but working out how to pay for them has become a pain point for the health industry. “Employers are saying, ‘I just can’t afford it,’” said CVS Health Chief Medical Officer Troy Brennan. In other pharmaceutical news: drugmakers' try to gain traction for next-generation sequencing but the going is slow; and Pfizer gets fast-track approval for a rare lung cancer drug.

More From BioPortfolio on "Faced With Paying For Pricey Gene-Therapy Treatments, Insurers Start Thinking Outside The Box"